Fallah, Jaleh

HIF Inhibitors: Status of Current Clinical Development

Fallah, J., & Rini, B. I. (2019) · Current Oncology Reports

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 308

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Fallah, J., Agrawal, S., Gittleman, H., Fiero, M. H., Subramaniam, S., John, C., Chen, W., Ricks, T. K., Niu, G., Fotenos, A., et al. (2023) · Clinical Cancer Research

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 255

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors

Fallah, J., Brave, M. H., Weinstock, C., Mehta, G. U., Bradford, D., Gittleman, H., Bloomquist, E. W., Charlab, R., Hamed, S. S., Miller, C. P., et al. (2022) · Clinical Cancer Research

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 180

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis

Fallah, J., Xu, J., Weinstock, C., Gao, X., Heiss, B. L., Maguire, W. F., Chang, E., Agrawal, S., Tang, S., Amiri-Kordestani, L., et al. (2024) · Journal of Clinical Oncology

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 86